AstraZeneca PLC appears to have teased out a positive result for Imfinzi in ovarian cancer – a setting that so far has proved intractable for anti-PD-(L)1 drugs. The data, toplined positive in April, concern the Duo-O study of an Avastin/Imfinzi/Lynparza triplet, and have been presented 3 June as an American Society of Clinical Oncology (ASCO) late-breaker.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?